File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Exosomal microRNA-486-3p mediates acquired resistance to anaplastic lymphoma kinase inhibitor in EML4-ALK translocated lung adenocarcinoma

TitleExosomal microRNA-486-3p mediates acquired resistance to anaplastic lymphoma kinase inhibitor in EML4-ALK translocated lung adenocarcinoma
Authors
Issue Date2018
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
23rd Medical Research Conference, Department of Medicine, The University of Hong Kong, 20 January 2018. In Hong Kong Medical Journal, 2018, v. 24 n. Suppl.1, p. 33, abstract no. 45 How to Cite?
AbstractIntroduction: Cancer cells could release exosomes to modulate the activities of other cells in the tumour microenvironment or at distant metastatic sites. The microRNAs (miRNAs) in cancer-derived exosomes may modulate drug resistance in recipient cells. Anaplastic lymphoma kinase (ALK) gene rearrangement is one therapeutic target in lung adenocarcinoma that indicates response to treatment with ALK-tyrosine kinase inhibitors (ALK-TKI). The role of intratumoural heterogeneity in drug resistance remains elusive. Method: We have established ALK-translocated lung adenocarcinoma cell lines and subclones. Expressions of miRNAs were detected by quantitative real-time polymerase chain reaction. Cell viability was determined by MTT assay. Results: The exosomes from ALK-TKI-resistant subpopulation of lung cancer cells could reduce drug sensitivity in originally sensitive subpopulations. Circulating exosomal miR-486-3p was found to be correlated with disease progression of EML4-ALK-translocated lung adenocarcinoma patient on ALK-TKI treatment. Conclusion: Exosomes released by drug-resistant subpopulation could induce resistance of other subpopulation of cells. Exosomal miRNA may serve as a novel therapeutic strategy and circulating prognostic marker for ALKtranslocated lung cancer.
Persistent Identifierhttp://hdl.handle.net/10722/256462
ISSN
2017 Impact Factor: 1.226
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorKwok, HH-
dc.contributor.authorNing, Z-
dc.contributor.authorChong, PWC-
dc.contributor.authorWan, TSK-
dc.contributor.authorNg, MHL-
dc.contributor.authorHo, GYF-
dc.contributor.authorIp, MSM-
dc.contributor.authorLam, CLD-
dc.date.accessioned2018-07-20T06:35:03Z-
dc.date.available2018-07-20T06:35:03Z-
dc.date.issued2018-
dc.identifier.citation23rd Medical Research Conference, Department of Medicine, The University of Hong Kong, 20 January 2018. In Hong Kong Medical Journal, 2018, v. 24 n. Suppl.1, p. 33, abstract no. 45-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/256462-
dc.description.abstractIntroduction: Cancer cells could release exosomes to modulate the activities of other cells in the tumour microenvironment or at distant metastatic sites. The microRNAs (miRNAs) in cancer-derived exosomes may modulate drug resistance in recipient cells. Anaplastic lymphoma kinase (ALK) gene rearrangement is one therapeutic target in lung adenocarcinoma that indicates response to treatment with ALK-tyrosine kinase inhibitors (ALK-TKI). The role of intratumoural heterogeneity in drug resistance remains elusive. Method: We have established ALK-translocated lung adenocarcinoma cell lines and subclones. Expressions of miRNAs were detected by quantitative real-time polymerase chain reaction. Cell viability was determined by MTT assay. Results: The exosomes from ALK-TKI-resistant subpopulation of lung cancer cells could reduce drug sensitivity in originally sensitive subpopulations. Circulating exosomal miR-486-3p was found to be correlated with disease progression of EML4-ALK-translocated lung adenocarcinoma patient on ALK-TKI treatment. Conclusion: Exosomes released by drug-resistant subpopulation could induce resistance of other subpopulation of cells. Exosomal miRNA may serve as a novel therapeutic strategy and circulating prognostic marker for ALKtranslocated lung cancer.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.relation.ispartof23rd Medical Research Conference, 2018-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleExosomal microRNA-486-3p mediates acquired resistance to anaplastic lymphoma kinase inhibitor in EML4-ALK translocated lung adenocarcinoma-
dc.typeConference_Paper-
dc.identifier.emailKwok, HH: kwokh@hku.hk-
dc.identifier.emailChong, PWC: peonyki@hku.hk-
dc.identifier.emailIp, MSM: msmip@hku.hk-
dc.identifier.emailLam, CLD: dcllam@hku.hk-
dc.identifier.authorityIp, MSM=rp00347-
dc.identifier.authorityLam, CLD=rp01345-
dc.identifier.hkuros286322-
dc.identifier.volume24-
dc.identifier.issueSuppl.1-
dc.identifier.spage33-
dc.identifier.epage33-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats